This bill makes it easier and cheaper for Medicare patients to access non-opioid pain medications. Starting in 2026, if you're on Medicare and have chronic pain conditions like fibromyalgia, diabetic nerve pain, endometriosis, or neuropathic pain, certain non-opioid drugs will be covered with little to no upfront costs. Specifically, these medications won't have a deductible (the amount you normally pay before insurance kicks in), and they'll be placed on the lowest cost-sharing tier, meaning you'll pay the least amount possible for them.

The bill also removes two common insurance barriers that can delay or prevent access to these drugs. Insurance companies won't be allowed to use "step therapy," which is when they force you to try a cheaper or opioid medication first before approving the non-opioid drug you actually need. They also can't require "prior authorization," which is when you have to get approval from your insurance company before your doctor can prescribe the medication. These changes apply only to non-opioid drugs that are FDA-approved for chronic pain, don't work through opioid receptors in the body, and meet certain cost thresholds. The goal is to give Medicare patients better access to pain management alternatives to opioids while keeping costs down.

Relief of Chronic Pain Act of 2025

Daines, Steve

Relief of Chronic Pain Act of 2025This bill reduces&nbsp;cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid drugs for chronic pain management.Specifically, the bill requires such drugs to be covered without a deductible and to be placed on the lowest cost-sharing tier (if any). The bill also prohibits the imposition of prior authorization requirements (i.e., requiring prior approval from a plan) or step therapy requirements (i.e., requiring the use of alternative drugs before a drug is covered under a plan) with respect to such drugs.